IVVD
NASDAQInvivyd Inc.
Invivyd Inc. (IVVD) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for IVVD, including 3 press releases and news items. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Revenue, TTM
- $58.37M
- Revenue growth
- +26.3%
- Net income, TTM
- -$107.33M
- Net margin
- -183.9%
- Free cash flow, TTM
- -$109.66M
- Cash
- $160.08M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks43-50%
2026-05-172026-11-08
Mix2090d
- Insider8(40%)
- Other7(35%)
- SEC Filings3(15%)
- Leadership1(5%)
- Earnings1(5%)
Activity · 52 weeks10856 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $0.5817, representing the closing price of Invivyd’s common stock on October 30, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25%
- PRInvivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measlesInvivyd is scaling up production toward clinical development in 2027There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measlesThe U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable
- PRInvivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeFLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injuryDesign includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 daysVYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants tested from original Wuhan through contemporary Omicron variantsFLINTLOCK is part of Invivyd’s broader REVOLUTION clinical program for VYD2311, including DECLARATION and LIBERTY Millions of individua
- PRInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $0.8165, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the fi
- SECInvivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccineVYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titersVYD2311 observed profile in LIBERTY indicates high measured neutralizing antiviral titers supporting the target profile for VYD2311 under study in the DECLARATION pivotal clinical studyInvivyd plans for DECLARATION and LIBERTY clinical studies to be
- PRInvivyd to Participate in Upcoming September Investor ConferencesNEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences: Citi’s 2026 Biopharma Back to School ConferenceWednesday, September 9, 2026 (Meetings Only)Location: New York, NY 2026 Cantor Global Healthcare ConferenceFireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)Meetings to FollowLocation: New York, NY H.C. Wainwright 28th Annual Global Investment ConferenceFireside Chat: Monday, September 14, 2026 at 5:00 PM ET (Webcast Link)Meetings Prior to Fireside ChatLocation: New York, NY
- PRInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $0.8799, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the
- INSIDERSEC Form 4 filed by Director Sheffield Ian4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sheffield Ian3 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Elia Marc4 - Invivyd, Inc. (0001832038) (Issuer)
- SECInvivyd Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTYMr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent DirectorIan Sheffield appointed to Invivyd’s Board of Directors as an independent directorDECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company. H
- INSIDERChief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERChief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERChief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERChief Legal Officer, Secretary Andersen Jill converted options into 170,000 shares and sold $52,781 worth of shares (67,962 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 56% to 283,774 units (SEC Form 4) to satisfy withholding obligation4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERChief Commercial Officer Lee Timothy Edward sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 52% to 178,937 units (SEC Form 4) (for tax liability)4 - Invivyd, Inc. (0001832038) (Issuer)
- SECSEC Form 144 filed by Invivyd Inc.144 - Invivyd, Inc. (0001832038) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Invivyd Inc.SCHEDULE 13G/A - Invivyd, Inc. (0001832038) (Subject)
- SECSEC Form 10-Q filed by Invivyd Inc.10-Q - Invivyd, Inc. (0001832038) (Filer)
- SECInvivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAchieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 millionCompleted rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demandDECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion LIBERTY study fully dosed with top-line data anticipated in late Q3 2026Strong balance sheet with Q2 2026 ending cash and cash equivalents of $160.1 million anticipated to provide r
- INSIDERSEC Form 4 filed by CMO and Chief Epidemiologist Mina Michael4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mina Michael3 - Invivyd, Inc. (0001832038) (Issuer)
IVVD FAQ
10 questionsWhat is the latest news on IVVD?
In the last 30 days Quantisnow tracked 3 wire items for IVVD: 3 press releases and news items. The most recent was published on November 3, 2026.What is IVVD revenue?
Invivyd Inc. (IVVD) reported $58.37M of revenue for the twelve months ended Jun 30, 2026. That is up 26.3% from the year before. Revenue for fiscal 2025 was $53.43M.Is IVVD profitable?
No. Invivyd Inc. reported a net loss of $107.33M for the twelve months ended Jun 30, 2026.How much cash and debt does IVVD have?
Invivyd Inc. reported $160.08M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does IVVD stock trade?
Invivyd Inc. (IVVD) is listed on NASDAQ.What sector and industry is IVVD in?
Invivyd Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Invivyd Inc. go public?
Invivyd Inc. (IVVD) completed its IPO in 2021.What are analysts saying about IVVD?
Across the last 7 analyst actions on Invivyd Inc., there were 3 upgrades and 1 downgrade. The most recent action was from BTIG Research: Buy with a $10.00 price target on 2025-12-22. Recent price targets range from $4.00 to $10.00.What companies are similar to IVVD?
Notable peers in the same industry include PFE (Pfizer Inc.), AZN (AstraZeneca PLC), VIR (Vir Biotechnology Inc.), MRNA (Moderna Inc.), NVAX (Novavax Inc.). Compare IVVD side-by-side with any of them on Quantisnow.How can I track IVVD on Quantisnow?
Quantisnow aggregates Invivyd Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IVVD to receive live email and push alerts on every new disclosure.